Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Moodys
Argus Health
McKinsey
Dow
Fish and Richardson
Covington
Teva
Citi

Generated: July 20, 2018

DrugPatentWatch Database Preview

JEVTANA KIT Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Jevtana Kit, and what generic alternatives are available?

Jevtana Kit is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this drug.

This drug has two hundred and five patent family members in fifty-eight countries.

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.
Drug patent expirations by year for JEVTANA KIT
Generic Entry Opportunity Date for JEVTANA KIT
Generic Entry Date for JEVTANA KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
SOLUTION;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for JEVTANA KIT
(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0;{3,10}.0;{4,7}]hept
(1S)-5beta,20-Epoxy-9-oxo-7beta,10beta-dimethoxytaxa-11-ene-1,2alpha,4alpha,13alpha-tetraol 2-benzoate 4-acetate 13-[(2R,3S)-2-hydroxy-3-(tert-butoxycarbonylamino)-3-phenylpropionate]
(2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1
1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)
183133-96-2
51F690397J
890654-44-1
A25044
AB01273971_02
AB01273971-01
ABP001072
AKOS032947285
AN-1492
BC252842
BMQGVNUXMIRLCK-OAGWZNDDSA-N
C45H57NO14
CABAZITAXEL
Cabazitaxel (Jevtana)
Cabazitaxel (USAN/INN)
Cabazitaxel [USAN:INN]
cabazitaxel acetonate
Cabazitaxel Injection
Cabazitaxel; TXD-258
Cabazitaxelum
CHEBI:63584
CHEMBL1201748
CS-0972
D02HSB
D09755
DB06772
DTXSID40171389
EX-A838
GTPL6798
HY-15459
J-011721
J-519981
javtana
Jevanta
Jevtana
Jevtana (TN)
MFCD18827611
MolPort-023-299-439
NCGC00346704-01
NSC-761432
NSC761432
RPR 116258A
RPR-116258A
s3022
SC-94928
SCHEMBL179674
SR-01000941585
SR-01000941585-1
Taxoid XRP6258
TXD 258
TXD258
UNII-51F690397J
W-5799
X7252
XRP 6258
XRP-6258
Xrp6258
ZINC85536932

US Patents and Regulatory Information for JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for JEVTANA KIT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,232,477 Methods of preparing new taxoids and pharmaceutical compositions containing them ➤ Try a Free Trial
6,331,635 Taxoids, their preparation and pharmaceutical compositions containing them ➤ Try a Free Trial
5,889,043 Taxoids, preparation thereof and pharmaceutical Compositions containing same ➤ Try a Free Trial
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for JEVTANA KIT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013010 Lithuania ➤ Try a Free Trial PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
2013000050 Germany ➤ Try a Free Trial PRODUCT NAME: ACETON-SOLVAT VON CABAZITAXEL; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
0130017 00077 Estonia ➤ Try a Free Trial PRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011
1667986/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: SWISSMEDIC 61543 06.04.2011
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
AstraZeneca
US Army
Fish and Richardson
Mallinckrodt
Harvard Business School
McKesson
Federal Trade Commission
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.